Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/02/2025 11:07 PDT] Allarity Therapeutics, Inc. (NASDAQ:ALLR), Up By 100% ($1.54) From $1.54 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/02/2025 06:12 PDT] ALLR Expected to Trade Up Short Term
• [08/28/2025 07:23 PDT] ALLR Expected to Trade Up After Bullish Patterns Develop
• [08/27/2025 10:29 PDT] Allarity Therapeutics, Inc. (NASDAQ:ALLR), Up By 100% ($1.4) From $1.4 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/27/2025 08:16 PDT] Allarity Therapeutics, Inc. (NASDAQ:ALLR), Up By 100% ($1.4) From $1.4 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/27/2025 07:27 PDT] ALLR Expected to Trade Up Short Term
• [08/26/2025 21:21 PDT] Market Maker Surveillance Report. ALLR, Bullishly Biased Price Friction For Tuesday, August 26th 2025
• [08/26/2025 10:29 PDT] ALLR SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [08/26/2025 10:29 PDT] Allarity Therapeutics, Inc. (NASDAQ:ALLR), Up By 100% ($1.79) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, August 26th 2025 at a Price of $1.79.
• [08/26/2025 10:29 PDT] Allarity Therapeutics, Inc. (NASDAQ:ALLR), Up By 100% ($0.96) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, August 12th 2025 at a Price of $0.957.
• [08/12/2025 10:29 PDT] ALLR SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [07/28/2025 07:20 PDT] ALLR Expected to Trade Down After Bearish Patterns Develop
• [07/24/2025 07:15 PDT] ALLR Expected to Trade Up After Bullish Patterns Develop